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The UGT2B17 gene polymorphism and bone mineral density in puberty. 
Isma Sohail. Jens Petter Berg. Johan Svartberg.  
Summary 
BACKGROUND: The uridine diphosphate-glucuronosyltransferase B17 is important for the 
excretion and thereby inactivation of testosterone. Testosterone is important for the bone 
growth in puberty. Low values of this hormone can cause male hypogonadism. Here we 
determine if there is any relationship between the UGT2B17 polymorphism and bone growth 
in puberty. Our agenda was to find if the distribution of the genotypes (insertion/insertion, 
insertion/deletion and deletion/deletion) were different for the groups with the highest 
increase in bone mass. Also we wanted to find out if there was any relationship between the 
UGT2B17 polymorphism and male hypogonadism. At last we studied if the polymorphism is 
associated with postmenopausal bone mass and loss. METHODS: The DNA samples used in 
this study were selected from three different groups 1) a cohort of children and adolescents 
recruited for studies of bone growth by Prof. Jens P Berg, Hormone Laboratory, Aker 
university hospital and UiO, 2) a substudy of male hypogonadism in the fourth survey of the 
Tromsø study by Prof. Johan Svartberg, UNN and UiTø, and 3) a study of postmenopausal 
bone loss (BUS-study) by Prof. Jan A. Falch, Endocrine Clinic, Aker university hospital and 
UiO. Genotyping was performed using primers for the insertion and deletion gene. The 
products were amplified using polymerase chain reaction (PCR) and separated on gel. 
RESULTS: There was a correlation between the gain in bone mineral density ultradistal 
forearm (BMDud) for boys in the puberty and the UGT2B17 polymorphism (p=0,009). The 
gain in BMDud was higher in boys homozygous for the UGT2B17 deletion polymorphism 
(0.100±0.037) compared with homozygotes for the insertion polymorphism (0.060±0.040) 
and heterozygotes (0.071±0.041). A statistically significant relationship was found between 
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the UGT2B17 polymorphism and BMD of trochanter major (p=0.017) and the BMD of total 
hip (p=0.016) for the whole group. The BMD of trochanter major showed higher values for 
the UGT2B17 deletion/deletion genotype (0.845±0.147) compared with the insertion/insertion 
genotype (0.786±0.115) and heterozygotes (0.767±0.119).Additionally, BMD of the total hip 
also showed higher values for the UGT2B17 deletion/deletion genotype (1.05±0.155) 
compared with the insertion/insertion genotype (0.992±0.131) and heterozygotes 
(0.962±0.138). The association between BMD of trochanter major and the UGT2B17 
polymorphism was also found for the boys analysed separately (p=0.02). There was also a 
statistically significant higher value for the UGT2B17 deletion/deletion genotype 
(0.904±0.157) compared with the insertion/insertion genotype (0.791±0.129) and 
heterozygotes (0.788±0.129). Substudy 2: There was no association between male 
hypogonadism and the UGT2B17 polymorphism. Substudy 3: There was no association 
between postmenopausal bone mass and loss and the UGT2B17 gene polymorphism. 
DISCUSSION:  The UGT2B17 gene polymorphism is playing a role in determining the bone 
mineral density in the puberty. The deletion/deletion polymorphism is associated with a 
higher serum IGF-1 value again stimulates to a higher bone mineral density in the puberty". 
Introduction 
Hereditity has a major contribution in the determination of bone mass. Studies have shown the 
importance of genetic factors for bone mass. In addition, several studies have indicated a 
correlation between bone mass and sex hormones 1. Sex hormones are again dependent of 
genetic factors. Also genes are important contributors for determining the total amount of sex 
hormones. This factor again decide the age of puberty and menopause.  Genes being central in 
the production and activation of sex hormones have previously been studied. In this study we 
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analysed a gene which is necessary for the inactivation of testosterone. The gene encodes for 
one of the uridine diphosphate-glucuronosyltransferases (UGTs), called UGT2B17.  
 
The UGTs 
Till today we are aware of  16 UGTs. The UGTs are integral membrane proteins of the 
endoplasmatic reticulum. Their function consists of attaching glucuronic acid to a vast 
number of lipophilic endobiotics and xenobiotics and thereby making them water soluble. 
This reaction facilitates the excretion of bilirubin, medicines and many other toxic 
metabolites. Glucuronidation occurs mainly in liver but also in various extrahepatic tissues, 
possibly affecting pharmacokinetics of drugs 2. The UGT genes can further be divided into 
two primary families, which are called UGT1 and UGT2 gene families, respectively.  There is 
also two other UGT families, UGT3 and UGT8. However, the catalytic activity of these 
enzymes still remain to be characterized3. There are seven members of the UGT2B subfamily. 
They have preference for glucuronidation of bile acids, steroids, fatty acids, carboxylic acids, 
phenols and carcinogens. The speciality of UGT2B17 is androgen glucuronidation4. The 
enzyme shows the highest activity for androsterone, testosterone and dihydrotestosterone and 
is mainly expressed in the prostate. In addition UGT2B15 can also glucuronidate these 
hormones. The genes for UGT2B15 and UGT2B17 are 95 % identical, but studies have 
showed that UGT2B17 has a higher biologic activity for testosterone5. There is described a 
gene deletion affecting this enzyme 6, which is related with inactivity of the enzyme. The 
occurrence of the gene shows ethnical variation. 70 % of Asians and 10 % of West Europeans 
are homozygous for the deletion.  
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 Probably this polymorphism has an effect on the glucuronidation activity. A Swedish study 7 
compared the excretion of testosterone in urine between Swedish and Korean men. The 
excretion was much lower for the Korean men. Furthermore, it was found that all the Koreans 
with lower excretion were homozygous for the deletion polymorphism. The deletion may 
result in a higher hormonal effect on account of the reduced inactivation of testosterone. 
Keeping in mind that UGT2B17 may influence the serum-testosterone level, which again 
plays a role for bone mass, we decided to test if there is a relationship between the UGT2B17 
insertion/deletion polymorphism and bone mass. Because the UGT2B17 del/del genotype 
subjects had negligible levels of testosterone-glucuronide in their urine in the Swedish-Korean 
study, this enzyme seems to be the most important for testosterone glucuronidation and 
testosterone excretion in vivo.  
Testosterone 
The androgen secretion is regulated by the hypothalamic-pituitary-testicular axis. The 
gonadotropin-releasing hormone, GnRH, is secreted from the hypothalamus in a pulsatile 
fashion. The pulsatile secretion of GnRH is followed by a pulsatile secretion of luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) from the gonadotrophs of the anterior 
pituitary. The pulsatile secretion of GnRH is essential for the LH and FSH secretion. On the 
other hand a continuous release of GnRH has an inhibitory effect on gonadotropin release. 
FSH plays a role in converting testosterone to estradiol by interacting with the receptors on 
the Sertoli cell membranes in the testis. 
In men, LH secretion is regulated primarily by negative feedback, as normal concentrations of 
gonadal steroids inhibit LH secretion. Testosterone acts on the hypothalamus to slow the 
hypothalamic pulse generator and decrease LH pulse frequency, probably by a mechanism 
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involving endogenous opioids. Testosterone also appears to inhibit LH release directly at the 
level of the pituitary. Some of these effects may be mediated by the local conversion of 
testosterone to estradiol. In adult men, estrogen inhibits LH secretion both by decreasing 
GnRH pulse frequency at the level of the hypothalamus and by reducing the amplitude of LH 
pulses via decreased pituitary responsiveness to GnRH . 
The synthesis and metabolism of testosterone to the active metabolites, 5-alpha-
dihydrotestosterone and 17-beta-estradiol happens in the Leydig cells in the testes. 
Cholesterol, the precursor steroid, can either be synthesized in the Leydig cell or derived from 
the plasma pool via uptake of low density lipoproteins. Five enzymatic processes are involved 
in the conversion of cholesterol to testosterone. The first reaction is the cleavage of the side 
chain of cholesterol which takes place in the mitochondria of the Leydig cells, while the other 
four reactions happens in the endoplasmatic reticulum. The first step is converting cholesterol 
to pregnenolone. This is a rate-limiting process, but the rate is rather determined by the rate of 
delivery of cholesterol to the enzyme in the inner mitochondrial membrane by the 
steroidogenic acute regulatory protein (StAR). This process is the main site of action of LH.  
Testosterone is transported in the plasma largely bound to albumin and sex hormone-binding 
globulin (SHBG, also called testosterone-binding globulin or TeBG). In normal men, 
approximately 2 percent of plasma testosterone is free or unbound, 44 percent is bound to 
SHBG, and 54 percent is bound to albumin and other proteins . Although albumin has about 
1000-fold lower affinity for testosterone binding than SHBG, it binds half or more of plasma 
testosterone because of its high concentration. Since nearly all of the albumin-bound 
testosterone is available for tissue uptake, bioavailable testosterone in plasma approximates 
the sum of free plus albumin-bound hormone. 
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The physiological actions of testosterone are the result of the combined effects of testosterone 
itself plus its active androgenic and estrogen metabolites. The major functions of androgens in 
males include regulation of gonadotropin secretion by the hypothalamic-pituitary system, 
initiation and maintenance of spermatogenesis and formation of the male phenotype during 
embryogenesis. In addition it is necessary to mediate many of the differentiation, growth-
promoting, and functional aspects of male sexual differentiation and virilization. 
The male hypogonadism 
The male hypogonadism refers to either a decrease in the male testosterone production or the 
sperm production. We can diagnose the deficiency by measuring the sperm quantity in semen 
or the testosterone level in serum. Depending on whether the defect is related to the testes or 
the hypothalamus-pituary system the hypogonadism is called primary or secondary. We can 
differentiate between these two abnormalities by measuring the level of LH and FSH. If the 
hypogonadism is primary the levels of these two hormones are increased as a response on the 
low androgen levels. In secondary hypogonadism these are reduced due to the defective 
production compared to the secondary hypogonadism when they are reduced. The primary 
hypogonadism is caused by diseases which affects the testes directly, such as viral orchitis, 
tumors, traumas, radiation, renal failure, Klinefelter syndrome and Prader-Willi syndrome. 
Prolactinomas, surgery of the pituary gland and hemochromatosis can cause secondary 
hypogonadism.  
The clinical features depend upon whether the defect includes the testosterone production, the 
sperm production or both. If the spermatogenesis is impaired this will result in just two 
defects, infertility and reduced testicular size. On the other hand impaired testosterone 
production will result in several clinical features depending on its time of onset during the 
reproductive development.  If the onset is after puberty the symptoms are decreased libido, 
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erectile dysfunction, reduced muscle mass and bone density, depression and anemia. Normal 
puberty is not possible if the testosterone deficiency is congenital.  
Bone synthesis 
Bone synthesis is a process starting early in the fetal life. The skeletal structure is formed by 
first making a pattern of cartilage and thereby replacing and modeling it with bone. This 
process is regulated by a large number of genes. Not only in the fetal life, but also during the 
adolescence and the adult life, modeling, is critical for formation of normal skeletal structures. 
After all this is the essential process for the growth of the skeleton. Another big part of the 
cellular activity related to bones is the remodeling, a process consisting of replacing and 
removing skeletal structures already present. This process is present already from fetal life, 
but it becomes the dominant form of bone cell activity after puberty.  
The remodeling is a process constituting of three parts: resorption, reversal and formation. 
First of all the resorption takes place. This is the process where the resorptive cells, the 
osteoclasts, remove mineral and matrix to a limited depth on the trabecular surface or within 
cortical bone. High concentrations of calcium has an inhibitory role in this process. Thereby 
the reversal follows. In this process mononuclear cells prepare the surface for the formation 
cells, the osteoblasts. At last the formation happens. Here the osteoblasts fill in with bone 
tissue until all the resorbed bone is completely replaced.  
Bone consists of two major parts, the cortical and the trabecular bone. The cortical bone is 
dense and compact and constitutes 80 % of the bone mass. Its major function is to give 
strength and protection. On the other hand the trabecular bone is found inside the long bones. 
This part of the skeleton is also an important contributor to mechanical support. During 
puberty and early adult life the trabecular thickening provides maximum skeletal mass and 
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strength, which is called peak bone mass. These processes are under the control of local and 
systemic factors.  
The major systemic regulators are the calcium-regulating hormones, parathyroid hormone 
(PTH) and calcitriol. In addition other hormones play a role in regulation, like 
glucocorticoids, thyroid hormones and sex hormones. The changes in the concentration of the 
systemic hormones plays a role in osteoporosis. This is the process which leads to bone loss, 
either because the resorption is increased or the formation is decreased. Estrogen deficiency 
has a central role in the pathogenesis of osteoporosis in postmenopausal women. Usually 
estrogen inhibits bone resorption, and a lack of this effect after the menopause results in 
increased bone resorption and rapid bone loss. The rate of loss slows down with time after 
menopause.   
Testosterone effects at the tissue level is to reduce bone resorption. In addition it has a modest 
effect on osteoblast proliferation. Testosterone increases the periosteal apposition resulting in 
a larger male compared to female skeleton during puberty 8. Investigation has shown an 
association between bone mass and testosterone decline with age in men 9.  
The loss of bone mass is not only related to the loss of endogenous testosterone with age, but 
also endogenous estrogens. Estrogens and testosterone use different pathways to inhibit 
osteclastic activity and bone resorption. Moreover data on bone health from the Framingham 
study were analyzed in 2006. In this study measurements of estradiol and testosterone were 
performed in serum in the early 80s from 793 men. The group was followed until 1999 and 
the incidence of hip fracture were calculated for those with low estradiol and testosterone 
levels. Interestingly, there was no significant increased risk for hip fracture among men with 
low testosterone. On the other hand there was a higher risk of hip fractures among the group 
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with low estradiol. The greatest risk for fractures was among the group with both low 
estradiol and testosterone levels 10.  
Osteoporosis 
Osteoporosis leads to increased risk of fractures and is defined as a skeletal disease with 
reduced bone mass. We call it established osteoporosis when there is sign of fractures in 
addition to osteoporosis. The fractures usually occur at the hip, vertebra and the forearm. The 
World Health Organization (WHO) has defined osteoporosis in women as a bone mineral 
density score 2.5 standard deviations or lower than the average for healthy, young women. 
The etiology is divided in primary and secondary causes. The primary causes are again 
divided in two major factors. Type I is postmenopausal osteoporosis associated with the 
postmenopausal estrogen deficiency. Type II is called senile osteoporosis, which is the age-
related loss of bone and appears in both sexes. Secondary osteoporosis is related to systemic 
diseases, like diseases in the gastrointestinal tract, endocrine diseases, kidney problems, bone 
marrow diseases, psychiatric diseases and so on. Risk factors for osteoporosis are age and 
being a woman. After the menopause women loose 3-5 % of their bone mass per year during 
5-10 years. Osteoporosis is also associated with polymorphisms in the LRP5-gene. Slim and 
tall persons, women entering an early menopause, inadequately nourished persons, smokers 
and alcohol users have a higher risk of getting osteoporosis. High values of homocystein is 
also a risk factor. The osteoporotic changes are greatest in the trabecular bone. We find the 
trabecular bone in the ends of the hollow tubular bones and in the vertebrae. Therefore this is 




Aims of the study 
The aim of this study was to analyse whether UGT2B17 insertion/deletion genotype plays a 
role for hypogonadism, bone mass and bone loss. 
1. In the first substudy we hypothesized that there is a relation between the UGT2B17 
polymorphism and bone mass in boys and girls in different stages of puberty and adolescence. 
2. In the second substudy we wanted to investigate the allele distribution of the UGT2B17 
insertion/deletion polymorphism in a group hypogonadal men compared to a control group. 
3. The aim of the third substudy was to analyse any role of the UGT2B17 insertion/deletion 
polymorphism for postmenopausal bone mass and bone loss. 
For all substudies several bone health related variables were available for comparison with the 
UGT2B17 genotype. 
Subjects and methods 
The DNA samples used in this study were selected from three different studies; 1) a cohort of 
children and adolescents recruited for studies of bone growth by Prof. Jens P Berg, Hormone 
Laboratory, Aker university hospital and UiO, 2) a substudy of male hypogonadism in the 
fourth survey of the Tromsø study by Prof. Johan Svartberg, UNN and UiTø, and 3) a study 
of postmenopausal bone loss (BUS-study) by Prof. Jan A. Falch, Endocrine Clinic, Aker 
university hospital and UiO.  
 
The first study group consisted of a cohort of 144 girls and 129 boys at the age of 8.7-17.0 
years at the start of the study. This population was followed for 3.8 years. At the baseline they 
were examined with measurements of height and weight, and blood samples for chemical and 
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genetic analyses were drawn. In addition measurements of body composition was performed 
by dual X-ray absortiometry (DXA) using a QDR 4500 device and analysed using available 
QDR software at the last follow-up. 
 
In a substudy of male hypogonadism conducted by Prof. Johan Svartberg, DNA was extracted 
from 178 samples (70 hypogonadal men and 108 controls) collected during the fourth survey 
of the Tromsø study. Gonadal status was determined by measuring serum concentrations of 
total testosterone, free testosterone and sex hormone binding globuline (SHBG) 11. Several 
variables such as height, weight, total testosterone, free testosterone, SHBG, bone mass, fat 
mass, waist circumference (WC), body mass index (BMI; calculated as kg/m2), and muscle 
mass were measured or calculated and recorded for these individuals. Height, weight and 
waist circumference were measured in standing subjects wearing light clothing without shoes, 
waist was measured at the umbilical line according to a written protocol. Waist circumference 
alone was used as an integrated measure of obesity and fat distribution, on the basis of studies 
suggesting that WC, as compared to waist-hip ratio (WHR) correlates better with visceral 
body fat measured by computed tomography or magnetic resonance imaging. 
 
The third study group consisted of 80 women who were a part of a study of bone mass 
estimated before and after menopause by Prof. Jan A. Falch. In addition, anthropometric 
(weight and height) and biochemical data were available. Bone mass measurements were 
done by DXA and ultrasound.  
 
Deoxyribonucleic acid was extracted from EDTA-blood in the Tromsø study. For the other 
two study groups extracted DNA was available. The gene regions of interest were amplified 
using the polymerase chain reaction (PCR). 
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 An insertion and deletion polymorphism of the UGT2B17-gene was studied essentially as 
described by (ref) 12. Allele specific PCR amplification of the deletion allele was expected to 
give an 884 bp product, whereas the insertion would give a 124 bp product based on the 
primers selected for the PCR. After many experiments we adjusted the concentration of the 
insertion primers to 0.12 μl/sample while the concentration of the deletion primers still was 
0.32 μl/sample. This is to balance the amplification rate of the genotypes. The PCR product of 
the insertion is shorter and preferentially amplified. The total concentration of one sample was 
25 µl. The different concentrations were necessary for the replication on account of the 
different sizes of the primers.  The forward and reverse primer combination for the insertion 
allele was 5’-GAATTCATCATGATCAACCG-3’and 5’-ACAGGCAACATTTTGTGATC-
3’, respectively, whereas the deletion allele was amplified by the combination of forward 
primer 5’-TGCACAGAGTTAAGAAATGGAGAGATGTG-3’ and reverse primer 5’-
GATCATCCTATATCCTGACAGAATTCTTTT-3’. The amplification was performed in the 
presence of 25 mM MgCl2 along with 5 mU/µl Taq polymerase and a reaction buffer. The 
samples were initially denatured at 95 °C for 5 min, followed by 30 cycles of denaturation (95 
°C for 30s), annealing (60 °C for 1 min), elongation (72 °C for 1 min) and final elongation at 
72 °C for 5 min.  Five μl of the PCR product was mixed with 2 μl of loading buffer, 
containing violet colour, prior to agarose gel electrophoresis. The samples were separated in a 
1% agarose gel in Tris-acetate-EDTA-buffer, TAE-buffer, stained with ethidium bromide, 
visualized under UV-light and photographed. For some of the samples a 3% agarose gel also 
was used to improve the visualisation of the 884 and 124 bp bands for the deletion and 
insertion products, respectively.  Subjects homozygous for the insertion alleles were indicated 
by 0, insertion/deletion heterozygotes by 1, and the homozygotes for the deletion by 2. 
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The study data were analyzed with respect to the UGT2B17 polymorphism genotype to find a 
correlation. This was done using the analysis of variation, ANOVA, combined with Student-
Neuman-Keuls test to identify stastically different groups. SDS scores for the continous 
variables were estimated and then compared with the UGT2B17 polymorphism genotype.  
Results 
Substudy 1 
In the first substudy of children and adolescents, measurements like height and weight were 
available as shown in table 1. All values were compared with the UGT2B17 genotype to find 
a relationship. The boys and girls were compared independently and together as a group. 
Measurements used for height and weight were from the start of the study (1992), while body 
fat mass and body lean mass values were measured in 1996. Gain in height and weight was 
found by calculating the difference between the values from 1996 and 1992. There were no 
statistically significant correlations between the gene polymorphism and variables like height, 
weight, body fat mass and body lean mass for both the whole group and boys and girls 
analysed independently. The gain of height for boys was greatest in the del/del group and 
reached almost statistically significant difference (p=0.071). 
 
Table 1 
Height, weight, body fat mass and body lean mass in substudy 1 (children and adolescents) 
among the three groups of UGT2B17 gene insertion/deletion polymorphism. Data are 
presented as mean ± SD. 
 
  Ins/ins Ins/Del Del/Del p 
         
n 116 108 23   
Age baseline (yr) 12.9±2.4 12.8±2.3 13.0±2.1 0.929 
Height baseline (cm) 154.4±15.2 154.2±14.0 153.7±11.7 0.978 
Weight baseline (kg) 46.7±12.7 46.3±12.1 45.8±10.9 0.940 
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Height gain (cm) 16.0±9.3 14.8±9.3 16.0±10.3 0.606 
Weight gain (kg) 15.9±8.1 15.7±7.1 16.4±9.4 0.903 
Body fat mass 1996 15012.0±6604.3 14867.6±7319.2 13300.5±5699.5 0.544 
Body lean mass 1996 42803.1±9591.1 42283.0±8638.0 43986.1±8155.8 0.703 
          
Boys         
n 55 51 12   
Age baseline (yr) 12.8±2.4 12.6±2.3 12.2±1.7 0.675 
Height baseline (cm) 155.5±16.5 154.3±14.0 150.1±9.3 0.519 
Weight baseline (kg) 46.9±12.8 45.0±11.2 42.6±7.4 0.444 
Height gain (cm) 16.6±8.5 18.7±8.0 22.3±7.7 0.071 
Weight gain (kg) 18.2±7.4 18.6±5.4 22.0±7.4 0.193 
Body fat mass 1996 11848.3±5716.9 10748.9±5151.9 10846.6±6122.6 0.571 
Body lean mass 1996 48392.0±10359.2 47663.6±9000.8 48562.0±8127.5 0.912 
          
Girls         
n 61 57 11   
Age baseline (yr) 12.9±2.4 12.9±2.3 13.9±2.3 0.453 
Height baseline (cm) 153.3±14.1 154.0±14.1 157.6±13.1 0.643 
Weight baseline (kg) 46.5±12.7 47.4±12.9 49.3±13.3 0.774 
Height gain (cm) 11.8±9.4 11.4±9.0 9.2±8.4 0.68 
Weight gain (kg) 13.8±8,3 13.1±7.4 10.3±7.4 0.394 
Body fat mass 1996 17864.5±6061.0 18552.8±7027.6 15977.5±3888.7 0.460 
Body lean mass 1996 37764.1±5028.3 37468.8±4503.2 38994.2±4597.8 0.624 
 
 
Bone mineral density in the distal (BMDd) and ultradistal (BMDud) forearm among children 
and adolescents. 
BMDd and BMDud values were measured three times (1992, 1993 and 1996). There was a 
correlation between the gain in BMDud for boys and the UGT2B17 polymorphism (p=0,009) 
(Table 2). The gain in BMDud was higher in boys homozygous for the UGT2B17 deletion 
polymorphism (0.100±0.037) compared with homozygotes for the insertion polymorphism 
(0.060±0.040) and heterozygotes (0.071±0.041). The same correlation was not found among 
girls (p=0.714).There were no other associations between forearm bone values and the 




Forearm bone mineral density among UGT2B17 insertion/deletion genotypes. Results are  
presented as mean±SD. 
 
  Ins/Ins Ins/Del Del/Del p 
     p 
n 116 108 23   
BMDd 1992 (g/cm2) 0.368±0.070 0.354±0.060 0.369±0.068 0.261 
BMDd 1993 (g/cm2) 0.387±0.078 0.377±0.068 0.386±0.075 0.608 
BMDd 1996 (g/cm2) 0.445±0.080 0.437±0.078 0.456±.0085 0.503 
BMDud 1992 (g/cm2) 0.350±0.069 0.339±0.054 0.347±0.058 0.429 
BMDud 1993 (g/cm2) 0.365±0.068 0.355±0.058 0.368±0.063 0.425 
BMDud 1996 (g/cm2) 0.400±0.069 0.392±0.063 0.416±0.081 0.250 
BMDd gain  0.078±0.050 0.083±0.058 0.087±0.064 0.676 
BMDud gain 0.050±0.043 0.053±0.041 0.070±0.048 0.139 
       
Boys      
n 55 51 12   
BMDd 1992 (g/cm2) 0.369±0.058 0.356±0.053 0.364±0.069 0.456 
BMDd 1993 (g/cm2) 0.389±0.071 0.377±0.061 0.379±0.082 0.676 
BMDd 1996 (g/cm2) 0.452±0.091 0.449±0.079 0.459±0.107 0.937 
BMDud 1992 (g/cm2) 0.365±0.068 0.349±0.055 0.353±0.072 0.406 
BMDud 1993 (g/cm2) 0.378±0.068 0.368±0.061 0.378±0.081 0.706 
BMDud 1996 (g/cm2) 0.425±0.069 0.420±0.066 0.453±0.093 0.342 
BMDd gain  0.083±0.050 0.093±0.066 0.095±0.067 0.606 
BMDud gain 0.060±0.040 0.071±0.041 0.100±0.037 0.009 
       
Girls      
n 61 57 11   
BMDd 1992 (g/cm2) 0.367±0.080 0.353±0.066 0.375±0.069 0.501 
BMDd 1993 (g/cm2) 0.385±0.083 0.377±0.075 0.393±0.071 0.769 
BMDd 1996 (g/cm2) 0.440±0.069 0.426±0.075 0.454±0.060 0.399 
BMDud 1992 (g/cm2) 0.336±0.068 0.330±0.051 0.339±0.040 0.828 
BMDud 1993 (g/cm2) 0.353±0.066 0.344±0.054 0.358±0.034 0.602 
BMDud 1996 (g/cm2) 0.377±0.061 0.366±0.047 0.376±0.039 0.506 
BMDd gain  0.073±0.051 0.073±0.049 0.078±0.062 0.946 
BMDud gain 0.042±0.044 0.036±0.033 0.037±0.035 0.714 
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Furthermore all BMD values were compared with the UGT2B17 polymorphism (Table 3). A 
statistically significant relationship was found between the UGT2B17 polymorphism and 
BMD of trochanter major (p=0.017) and the BMD of total hip (p=0.016) for the pooled group. 
The BMD of trochanter major showed higher values for the UGT2B17 deletion/deletion 
genotype (0.845±0.147) compared with the insertion/insertion genotype (0.786±0.115) and 
heterozygotes (0.767±0.119).Additionally, BMD of the total hip also showed higher values 
for the UGT2B17 deletion/deletion genotype (1.05±0.155) compared with the 
insertion/insertion genotype (0.992±0.131) and heterozygotes (0.962±0.138). The association 
between BMD of trochanter major and the UGT2B17 polymorphism was also found for the 
boys analysed separately (p=0.02). There was also a statistically significant higher value for 
the UGT2B17 deletion/deletion genotype (0.904±0.157) compared with the insertion/insertion 
genotype (0.791±0.129) and heterozygotes (0.788±0.129). For girls such an association was 
not found, but after calculating the SDS score for BMD of the trochanter and the total hip we 
found a statistically significant association between the SDS score for the BMD of the total 
hip and the UGT2B17 polymorphism (0.042). 
Table 3 
Bone mineral density among the UGT2B17 insertion/deletion genotypes. Data are presented 
as mean ± SD. 
  Ins/Ins Ins/Del Del/Del p 
          
n 116 108 23   
BMD spine (L1-L4) (g/cm2) 0.968±0.144 0.960±0.144 0.985±0.136 0.733 
BMD femoral neck (g/cm2) 0.901±0.121 0.891±0.131 0.949±0.145 0.140 
BMD trochanter (g/cm2) 0.786±0.115 0.767±0.119 0.845±0.147 0.017 
BMD total hip (g/cm2) 0.992±0.131 0.962±0.138 1.050±0.155 0.016 
BMD whole body (g/cm2) 1.086±0.117 1.071±0.119 1.111±0.118 0.518 
SDS BMD trochanter 0.183±0.968 0.040±1.019 0.675±1.038 0.022 
SDS BMD total hip 0.139±1.014 .- 0.490±1.009 0.042 
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0.136±1.009 
          
Boys         
n 55 51 12   
BMD spine (L1-L4) (g/cm2) 0.935±0.155 0.935±0.149 0.949±0.137 0.954 
BMD femoral neck (g/cm2) 0.908±0.133 0.919±0.149 0.997±0.172 0.154 
BMD trochanter (g/cm2) 0.791±0.129 0.788±0.129 0.904±0.157 0.020 
BMD total hip (g/cm2) 0.998±0.146 0.987±0.155 1.092±0.188 0.104 
BMD whole body (g/cm2) 1.096±0.128 1.086±0.133 0.124±0.146 0.664 




0.012±0.975 0.910±1.063 0.011 
SDS BMD total hip 0.064±0.959 
.-
0.001±0.989 0.763±1.177 0.056 
          
Girls         
n 61 57 11   
BMD spine (L1-L4) (g/cm2) 0.998±0.128 0.982±0.137 1.024±0.130 0.582 
BMD femoral neck (g/cm2) 0.895±0.110 0.866±0.107 0.879±0.090 0.299 
BMD trochanter (g/cm2) 0.781±0.101 0.747±0.106 0.781±0.109 0.195 
BMD total hip (g/cm2) 0.987±0.118 0.940±0.117 1.001±0.096 0.056 
BMD whole body (g/cm2) 1.077±0.106 1.058±0.104 1.099±0.083 0.396 
SDS BMD trochanter 0.370±0.904 0.087±1.064 0.418±0.995 0.253 
SDS BMD total hip 0.207±1.065 
.-
0.257±1.026 0.112±0.726 0.042 
 
Figure 1.  
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Box-plot of BMD values for trochanter major in the three different genotypes for boys and 
girls. The values for the BMD is higher for the deletion/deletion genotype. 
 
Figure 2. 
 Box-plot of BMD values for total hip in the three different genotypes for boys and girls. The 
values for the BMD is higher for the deletion/deletion genotype.  
Serum-IGF-1, serum-testosterone and the UGT2B17 gene polymorphism 
The relationship between serum-IGF-1 values and serum testosterone was analysed for the 
males in the first substudy (Fig 3). Serum-IGF-1 values were statistically significantly higher 
among the deletion/deletion genotype (p=0.001, One Way ANOVA and Student-Neuman 













Scatter-plot of estimated free serum-testosterone and serum-IGF1 levels among UGT2B17 





























Box plot of estimated free serum testosterone in boys according among the different 
UGT2B17 insertion/deletion genotypes. There is no statistically significant difference among 




Measurements of height, weight and BMD were also available for the the UGT2B17 analysis 
of the study of male hypogonadism in the Tromso study. There were no statistically 
significant associations were between the UGT2B17 insertion/deletion polymorphism and the 
anthropometric variables. The genotype distribution among subjects with hypogonadism and 
controls was similar. 
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 Substudy 3 
In the study of postmenopausal bone mass and bone loss in the BUS-project no association 
was found between UGT2B17 insertion/deletion genotype and measurements of height, 
weight or BMD. In addition serum values from the BUS-project were available. By ANOVA 
we found a statistically significant lower serum calcium levels measured in 1995 for the 
deletion/deletion genotype compared to the insertion/insertion and insertion/deletion 
genotypes (Table 4). Also the decrease in serum calcium from 1993 to 1995 was greater for 
this group.  
 
Table 4 
Total serum calcium values in postmenopausal women measured in 1993 and 1995 and the 
decrease in total serum calcium among different UGT2B17 insertion/deletion genotypes. 
Values are in mmol/L. 
 
 The mean values  
n 32 23 12  
 INS/INS INS/DEL DEL/DEL p 
S-calcium 93 2,3000 2,3100 2,2850 0,7320 
S-calcium 95 2,3200 2,3300 2,2600 0,0450 
Delta S-calcium 93-95 -0,0106 -0,0300 0,0475 0,0150 
 
Another interesting finding was the reduction in FSH for these women. Using data from 1993 
and 1995 we found a statistically significant difference (p=0,046) between the genotypes for 
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Serum FSH values in postmenopausal women measured in 1993 and 1995 and the change in 
FSH among different UGT2B17 insertion/deletion genotypes. Values are in mIU/L. 
 The mean values  
n 32 23 12 p 
 INS/INS INS/DEL DEL/DEL  
S-FSH 93 63,4220 55,6700 63,9250 0,3660 
S-FSH 95 63,7870 58,2090 54,0170 0,4000 




The relationship between serum-IGF-1 levels and the genotype of the UGT2B17 in boys was 
a quite interesting finding. Until now there is not any study indicating a role of the UGT2B17 
genotype for the serum IGF-1 concentration. IGF-1 is important for skeletal growth. Thereby 
the genotype may play an indirect role for the growth of the skeleton. This association to the 
skeleton was also shown by the correlation with BMD of the forearm. The genes effect on 
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bone mass could be a combined result of the effect on IGF-1 and on testosterone excretion, 
but there was no difference in serum testosterone levels.  
We did not find any association between the gene polymorphism and measurements of height, 
weight, body fat mass, and body lean mass. On the other hand studies have shown that growth 
hormone combined with an anabolic steroid gives a greater height gain than treatment with 
growth hormone alone 13. This was also shown in a study of two children who entered 
puberty with a short stature. This indicates a correlation between sex steroid hormone lev
and height. It was surprising to not find an association between the gene polymorphism a
height. Maybe an association could have been found if the study group had been bigger. There 




Another study has shown that UGT2B17 genotypes are predictors of fat mass in men14. In our 
study there is no relation between the childrens fat mass and UGT2B17. There is normally a 
decrease in testosterone levels with age. It can be speculated that the influence of the 
UGT2B17 genotype on serum testosterone and fat mass is greater in older men compared to 
boys.  
 
The correlation between BMD for total hip and trochanter major in children compared with 
the Tromsø study and the BUS study is surprising. It is also necessary to have in mind that the 
BMD of the total hip and trochanter major are two depending factors. The BMD of the total 
hip contains the BMD of the trochanter. We suggest that the cause of such a relation only for 
this group indicate that the polymorphism in the UGT2B17 gene plays a role for the BMD in 
puberty, but not for the final BMD. In the other two groups we find people who have come to 
a steady state or decline of BMD, which may preclude an association. Probably the UGT2B17 
gene polymorphism has an effect for the gain in bone mass during puberty.  
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There was an association between BMD of trochanter major and the UGT2B17 
polymorphism for the boys, while the values for girls were not statistically significantly 
different. The UGT2B17 gene may play a bigger role for boys. Several studies have indicated 
that testosterone increases bone mass. Therefore it is not so surprising that UGT2B17 also 
plays a role in determining bone mass15. Still there is a lack of studies indicating the 
relationship between this gene and bone mass. It can not be excluded that repeated testing of 
associations may give false statistically significant p-values and that the observed association 
is spurious. Another drawback of this study was the lack of power. The group of children was 
small and with a greater amount of children we had had the chance to find more associations. 
 
For all the significant values like BMDud, BMD of trochanter major and BMD of total hip we 
found higher values for the deletion/deletion polymorphism. As mentioned in the introduction 
the lack of testosterone inactivation in this genotype may result in higher local effects of 
testosterone and thereby higher bone mineral density.  
There is also a point to be noted that there was no association between the UGT2B17 
polymorphism and male hypogonadism. None of the polymorphisms were overrepresented in 
this group compared to controls. Male hypogonadism is a condition defined by a low serum 
testosterone value. Our result indicate that decreased production of testosterone is more 
important for serum testosterone levels than genetic variation in the UGT2B17 gene.   
Neither was there any association between BMD in postmenopausal women and the gene 
polymorphism. This indicates also that there the genotype has no relationship to 
postmenopausal bone loss. On the other hand we found a decrease in serum calcium and 
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serum FSH for this group. The decrease in calcium was greater for the deletion/deletion 
genotype. These differences among the genotypes seem not to be of clinical importance. 
In the beginning it was difficult to amplify both the gene for insertion and deletion with a 
concentration of 0.32 μl primer for each sample. Allele specific PCR amplification of the 
deletion allele was expected to give an 884 bp product, whereas the insertion would give a 
124 bp product. The PCR product indicating deletion consisted of 884 bp while the insertion 
product only consisted of 124 bp. In the heterozygotes the gene for insertion competed out the 
gene for deletion in the initial experiments and the products seemed like homozygotes for 
insertion. After many experiments we adjusted the concentration of the insertion primer to 
0.12 μl/sample while the concentration of the deletion primer still was 0.32 μl/sample. 76 of 
the Tromsø samples were still difficult to amplify. For these samples parallel PCR were run, 
one with separate primer sets for the insertion alone and one for the deletion alone. Under 
these circumstances both the genes had optimal conditions to be replicated. 
 
To summarize this study we have found some associations between the UGT2B17 
deletion/deletion genotype and measurements of bone mass, and serum levels of IGF1, total 
calcium and FSH. Specifically, there was a correlation between the genotypes and BMD in 
the trochanter major, total hip, and the gain in BMDud among boys. The deletion/deletion 
genotype was associated with increased serum IGF1 levels independent of estimated free 
testosterone, and seemed to give a higher bone mineral density and to be important for growth 
in the puberty. Details about this relationship remains to be characterized. Our study shows 
that there is no relationship between male hypogonadism and the UGT2B17 genotypes. 
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